Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Therapeutic implications of menin inhibition in acute leukemias

Clinical Trial Results - Cancer Currents Blog - NCI

Clinical Trial Results National Cancer Institute

Clinical Trial Results National Cancer Institute

Clinical Trial Results National Cancer Institute

Revumenib Shows Promise in Acute Leukemia - CancerConnect

Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines

Treatment National Cancer Institute

PDF) Therapeutic targeting of leukemia stem cells in acute myeloid

Edward Carr on LinkedIn: Revumenib Shows Promise for Advanced

Revumenib: a new therapy for AML patients

Drug 'cures' 33% of patients with aggressive leukaemia in early

Hayarpi Javrushyan on LinkedIn: Revumenib Shows Promise for

MEN1 mutations mediate clinical resistance to menin inhibition

Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI